PTC Therapeutics (PTCT) Stock Forecast & Price Target

Compare

364 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PTCT Analyst Ratings

Moderate Buy

8 Buy

5 Hold

0 Sell

Based on 13 analysts giving stock ratings to

PTC

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PTCT Stock 12 Month Forecast

Average Price Target

$63.08

▲(31.80%Upside)

Based on 13 Wall Street analysts offering 12 month price targets for PTC Therapeutics in the last 3 months. The average price target is $63.08 with a high forecast of $113.00 and a low forecast of $40.00. The average price target represents a 31.80% change from the last price of $47.86.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"$30","51":"$51","72":"$72","93":"$93","114":"$114"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":113,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$113.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":63.08,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$63.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,51,72,93,114],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.52,54.403076923076924,59.28615384615385,64.16923076923077,69.05230769230769,73.9353846153846,78.81846153846153,83.70153846153846,88.58461538461538,93.4676923076923,98.35076923076923,103.23384615384614,108.11692307692307,{"y":113,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.52,50.56307692307693,51.60615384615385,52.64923076923077,53.69230769230769,54.73538461538462,55.77846153846154,56.821538461538466,57.864615384615384,58.90769230769231,59.95076923076923,60.99384615384615,62.036923076923074,{"y":63.08,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.52,48.78769230769231,48.05538461538462,47.323076923076925,46.59076923076923,45.85846153846154,45.12615384615385,44.393846153846155,43.66153846153846,42.92923076923077,42.19692307692308,41.464615384615385,40.73230769230769,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":34.16,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.36,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.17,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.69,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.32,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.05,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.07,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.14,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.88,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.26,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$113.00

Average Price Target$63.08

Lowest Price Target$40.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$50

Hold

4.47%

Upside

Reiterated

05/23/25

PTC Therapeutics' overall score is driven by strong financial improvements, particularly in revenue and cash flow. Positive earnings call sentiments and promising corporate events further bolster the score. However, negative equity and technical indicators suggest caution, tempering the overall outlook.

Tiago FauthWells Fargo

Wells Fargo

$68→$74

Buy

54.62%

Upside

Reiterated

05/27/25

Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), PTC Therapeutics (PTCT)

Tazeen AhmadBank of America Securities

Bank of America Securities

$68

Buy

42.08%

Upside

Reiterated

05/14/25

Bank of America Securities Sticks to Its Buy Rating for PTC Therapeutics (PTCT)

Eric JosephJ.P. Morgan

J.P. Morgan

$67

Buy

39.99%

Upside

Reiterated

05/13/25

PTC Therapeutics: Strategic Growth and Market Expansion Drive Buy Rating

Joel BeattyRobert W. Baird

Robert W. Baird

$70→$66

Buy

37.90%

Upside

Reiterated

05/07/25

PTC Therapeutics price target lowered to $66 from $70 at BairdPTC Therapeutics price target lowered to $66 from $70 at Baird

Gena WangBarclays

Barclays

$56→$42

Hold

-12.24%

Downside

Reiterated

05/07/25

PTC Therapeutics (PTCT) PT Lowered to $42 at BarclaysBarclays analyst Gena Wang lowered the price target on PTC Therapeutics (NASDAQ: PTCT) to $42.00 (from $56.00) while maintaining a Equalweight rating.

Geoff MeachamCiti

Citi

$50→$40

Hold

-16.42%

Downside

Upgraded

05/06/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Agilent (NYSE: A), Andlauer Healthcare Group (Other OTC: ANDHF) and PTC Therapeutics (NASDAQ: PTCT)

Judah FrommerMorgan Stanley

Morgan Stanley

$70

Buy

46.26%

Upside

Reiterated

05/06/25

PTC Therapeutics: Strong Financial Performance and Promising Product Launches Justify Buy Rating

Joseph ThomeTD Cowen

TD Cowen

$60→$52

Hold

8.65%

Upside

Reiterated

05/06/25

PTC Therapeutics: Balancing Strategic Success with Regulatory Uncertainty - A Hold Rating Analysis

Louise ChenScotiabank

Scotiabank

$55

Hold

14.92%

Upside

Reiterated

05/06/25

Scotiabank Keeps Their Hold Rating on PTC Therapeutics (PTCT)

Joseph SchwartzLeerink Partners

Leerink Partners

$52

Hold

8.65%

Upside

Reiterated

05/05/25

Leerink Partners reiterates Market Perform Rating on PTC Therapeutics (PTCT)Leerink Partners analyst Joseph P. Schwartz reiterated a Market Perform rating and $52.00 price target on PTC Therapeutics (NASDAQ: PTCT)

Sami CorwinWilliam Blair

William Blair

―

Buy

―

Reiterated

05/05/25

Analysts Offer Insights on Healthcare Companies: BioNTech SE (NASDAQ: BNTX), PTC Therapeutics (NASDAQ: PTCT) and Larimar Therapeutics (NASDAQ: LRMR)

Brian AbrahamsRBC Capital

RBC Capital

$65→$58

Buy

21.19%

Upside

Reiterated

05/05/25

PTC Therapeutics price target lowered to $57 from $65 at RBC CapitalPTC Therapeutics price target lowered to $57 from $65 at RBC Capital

Kristen KluskaCantor Fitzgerald

Cantor Fitzgerald

$113

Buy

136.11%

Upside

Reiterated

03/03/25

Cantor Fitzgerald reiterates Overweight Rating on PTC Therapeutics (PTCT)Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $113.00 price target on PTC Therapeutics (NASDAQ: PTCT).

Paul ChoiGoldman Sachs

Goldman Sachs

$32→$42

Sell

-12.24%

Downside

Reiterated

12/03/24

PTC Therapeutics (PTCT) PT Raised to $42 at Goldman SachsGoldman Sachs analyst Paul Choi raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $42.00 (from $32.00) while maintaining a Sell rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$50

Hold

4.47%

Upside

Reiterated

05/23/25

Tiago FauthWells Fargo

Wells Fargo

$68→$74

Buy

54.62%

Upside

Reiterated

05/27/25

Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), PTC Therapeutics (PTCT)

Tazeen AhmadBank of America Securities

Bank of America Securities

$68

Buy

42.08%

Upside

Reiterated

05/14/25

Bank of America Securities Sticks to Its Buy Rating for PTC Therapeutics (PTCT)

Eric JosephJ.P. Morgan

J.P. Morgan

$67

Buy

39.99%

Upside

Reiterated

05/13/25

PTC Therapeutics: Strategic Growth and Market Expansion Drive Buy Rating

Joel BeattyRobert W. Baird

Robert W. Baird

$70→$66

Buy

37.90%

Upside

Reiterated

05/07/25

PTC Therapeutics price target lowered to $66 from $70 at BairdPTC Therapeutics price target lowered to $66 from $70 at Baird

Gena WangBarclays

Barclays

$56→$42

Hold

-12.24%

Downside

Reiterated

05/07/25

Geoff MeachamCiti

Citi

$50→$40

Hold

-16.42%

Downside

Upgraded

05/06/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Agilent (NYSE: A), Andlauer Healthcare Group (Other OTC: ANDHF) and PTC Therapeutics (NASDAQ: PTCT)

Judah FrommerMorgan Stanley

Morgan Stanley

$70

Buy

46.26%

Upside

Reiterated

05/06/25

PTC Therapeutics: Strong Financial Performance and Promising Product Launches Justify Buy Rating

Joseph ThomeTD Cowen

TD Cowen

$60→$52

Hold

8.65%

Upside

Reiterated

05/06/25

PTC Therapeutics: Balancing Strategic Success with Regulatory Uncertainty - A Hold Rating Analysis

Louise ChenScotiabank

Scotiabank

$55

Hold

14.92%

Upside

Reiterated

05/06/25

Scotiabank Keeps Their Hold Rating on PTC Therapeutics (PTCT)

Joseph SchwartzLeerink Partners

Leerink Partners

$52

Hold

8.65%

Upside

Reiterated

05/05/25

Sami CorwinWilliam Blair

William Blair

―

Buy

―

Reiterated

05/05/25

Analysts Offer Insights on Healthcare Companies: BioNTech SE (NASDAQ: BNTX), PTC Therapeutics (NASDAQ: PTCT) and Larimar Therapeutics (NASDAQ: LRMR)

Brian AbrahamsRBC Capital

RBC Capital

$65→$58

Buy

21.19%

Upside

Reiterated

05/05/25

PTC Therapeutics price target lowered to $57 from $65 at RBC CapitalPTC Therapeutics price target lowered to $57 from $65 at RBC Capital

Kristen KluskaCantor Fitzgerald

Cantor Fitzgerald

$113

Buy

136.11%

Upside

Reiterated

03/03/25

Paul ChoiGoldman Sachs

Goldman Sachs

$32→$42

Sell

-12.24%

Downside

Reiterated

12/03/24

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering PTC Therapeutics

1 Month

xxx

Success Rate

13/17 ratings generated profit

Average Return

+6.59%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 76.47% of your transactions generating a profit, with an average return of +6.59% per trade.

3 Months

xxx

Success Rate

13/17 ratings generated profit

Average Return

+12.84%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 76.47% of your transactions generating a profit, with an average return of +12.84% per trade.

1 Year

Joel BeattyRobert W. Baird

Success Rate

15/17 ratings generated profit

Average Return

+38.81%

reiterated a buy rating 22 days ago

Copying Joel Beatty's trades and holding each position for 1 Year would result in 88.24% of your transactions generating a profit, with an average return of +38.81% per trade.

2 Years

xxx

Success Rate

15/17 ratings generated profit

Average Return

+57.33%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 88.24% of your transactions generating a profit, with an average return of +57.33% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PTCT Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PTCT has received 24 Buy Ratings, 14 Hold Ratings, and 1 Sell Ratings. PTCT average Analyst price target in the past 3 months is 63.08.

Each month's total comprises the sum of three months' worth of ratings.

PTCT Financial Forecast

PTCT Earnings Forecast

Next quarter’s earnings estimate for PTCT is -$1.04 with a range of -$1.94 to -$0.37. The previous quarter’s EPS was $10.04. PTCT beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.23% of the time in the same period. In the last calendar year PTCT has Outperformed its overall industry.

PTCT Sales Forecast

Next quarter’s sales forecast for PTCT is $174.18M with a range of $149.00M to $198.50M. The previous quarter’s sales results were $1.18B. PTCT beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.59% of the time in the same period. In the last calendar year PTCT has Outperformed its overall industry.

PTCT Stock Forecast FAQ

What is PTCT’s average 12-month price target, according to analysts?

Based on analyst ratings, PTC Therapeutics’s 12-month average price target is 63.08.

What is PTCT’s upside potential, based on the analysts’ average price target?

PTC Therapeutics has 31.80% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PTCT a Buy, Sell or Hold?

PTC Therapeutics has a consensus rating of Moderate Buy which is based on 8 buy ratings, 5 hold ratings and 0 sell ratings.

What is PTC Therapeutics’s price target?

The average price target for PTC Therapeutics is 63.08. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $113.00 ,the lowest forecast is $40.00. The average price target represents 31.80% Increase from the current price of $47.86.

What do analysts say about PTC Therapeutics?

PTC Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of PTCT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

PTC Therapeutics (PTCT) Stock Forecast & Price Target

PTCT Analyst Ratings

PTCT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering PTC Therapeutics

PTCT Analyst Recommendation Trends

PTCT Financial Forecast

PTCT Earnings Forecast

PTCT Sales Forecast

PTCT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts